The frequency of CD163+ M2-like MØs has been reported to be notably increased in acute and chronic myeloid leukaemia [43,44], chronic lymphocytic leukaemia [45], multiple myeloma [46] and also adult ALL [47]. Here, CD163 is linked to plasma cell myeloma.